Genmab reports Phase I/II data for Rina-S in ovarian cancer

Phase 2Rina-SNeutral

AI Analysis

Summary

Genmab announced Phase I/II data from Part C of the RAINFOL-01 trial of rinatabart sesutecan in platinum-resistant ovarian cancer patients. No details on the data outcomes or patient numbers were provided in the announcement.

Clinical Trial Data

Phase

Phase I/II

Importance:5/10

Sentiment:

0.00

oncologyovarian cancerphase 1/2clinical data

Related Companies

$GMAB

Read the original article

Published by Clinical Trials Arena on October 5, 2026 7:56 AM

Read Original